SABLE: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without Benlysta (Belimumab) (116543) First published 16/10/2013 Last updated 17/09/2025 EU PAS number:EUPAS4966 Study Finalised